A randomized, triple-blinded controlled clinical study with a novel disease-modifying drug combination in equine lameness-associated osteoarthritis
Authors: E. Skiöldebrand, S. Adepu, C. Lützelschwab, S. Nyström, A. Lindahl, K. Abrahamsson-Aurell, E. Hansson
Journal: Osteoarthritis and Cartilage Open
Summary
# Editorial Summary: Novel Disease-Modifying Treatment for Equine Osteoarthritis Researchers in Sweden conducted a rigorous triple-blinded phase III trial comparing a novel drug combination (sildenafil, mepivacaine, and glucose) against the conventional corticosteroid benchmark Celestone® bifas® in 20 horses presenting with mild carpal osteoarthritis and associated lameness. Both treatments were administered intra-articularly at two-week intervals, with efficacy evaluated through objective gait analysis (Lameness Locator), subjective visual assessment, and synovial fluid biomarkers reflecting cartilage and bone turnover (BGN262 and COMP156). The experimental combination significantly reduced synovial BGN262 levels (P = 0.002), suggesting reduced cartilage degradation, whilst the control group showed a significant increase in COMP156 (P = 0.002), indicating ongoing matrix remodelling; clinically, the novel treatment improved flexion test scores and trotting gait quality compared to corticosteroid injection. For practitioners managing OA-associated lameness, these results suggest the novel combination may offer disease-modifying benefits beyond symptomatic relief, potentially addressing underlying pathology rather than simply masking clinical signs, though the small sample size warrants cautious interpretation pending larger confirmatory studies.
Read the full abstract on PubMed
Practical Takeaways
- •A novel three-drug intra-articular combination showed superior clinical outcomes for carpal OA compared to standard steroid treatment, with measurable improvements in flexion and gait quality
- •Biomarker monitoring (BGN262 and COMP156) may help objectively track cartilage status and treatment response rather than relying on clinical observation alone
- •This novel combination appears safe with no reported adverse events, offering a potential alternative to conventional corticosteroid injections for managing OA-associated lameness
Key Findings
- •Treatment combination (sildenafil, mepivacaine, glucose) significantly reduced synovial fluid BGN262 levels (P=0.002), indicating reduced cartilage degradation
- •Celestone bifas increased COMP156 levels (P=0.002), suggesting ongoing cartilage remodeling
- •Treatment combination improved flexion test scores compared to Celestone bifas (P=0.033)
- •Treatment combination improved trotting gait quality compared to Celestone bifas (P=0.044); no adverse events reported in either group